Date: Nov 03, 2016 Source: Business Wire (
click here to go to the source)
CAMBRIDGE, Mass. & LEIPZIG, Germany--(BUSINESS WIRE)--EnBiotix, Inc., a product-focused bioengineering company leveraging systems and synthetic biology platforms to combat the global rise of drug-resistant and drug-tolerant bacterial infections, today announced the completion of an asset acquisition of AMP Therapeutics GmbH ("AMPT"), an anti-microbial peptide portfolio company of Boehringer Ingelheim Venture Fund and Novartis Venture Fund. In connection with the acquisition, EnBiotix has established EnBiotix GmbH. EnBiotix has also initiated a collaboration with Leipzig University and AMPT's scientific co-founder, Professor Ralf Hoffmann, Ph.D.
"AMPT has discovered and developed unique families of anti-microbial peptides which are very potent, non-toxic to human cells and which possess broad spectrum anti-bacterial activity," said Jeffrey D. Wager, M.D., Chairman & CEO of EnBiotix. "These peptides represent exciting potential candidates as payloads for our engineered phage platform and as stand-alone therapies for both human and animal health indications. In addition, by establishing EnBiotix GmbH to facilitate our acquisition of AMPT assets, we are now well-positioned to pursue a variety of European partnering and fundraising activities in both the private and public sectors."
"The acquisition of AMPT by EnBiotix represents a very synergistic fit between the two companies, and should substantially enhance corporate value for both sets of shareholders," said Martin F. Heidecker, Ph.D., MBA, Managing Director of Boehringer Ingelheim Venture Fund USA Inc. "As part of our mission to invest in and support early stage, innovative research that can benefit patients worldwide, we strongly support this business combination."
The AMPT anti-microbial peptides address significant unmet medical needs and provide an alternative to antibiotics in human and animal health, particularly in an era of unprecedented bacterial resistance to traditional antibiotics. In conjunction with the acquisition, EnBiotix has also initiated a collaboration with Leipzig University and Professor Ralf Hoffmann. The collaboration between EnBiotix GmbH and the Hoffmann Lab will work to optimize anti-microbial peptides for a variety of indications, beginning with ventilator associated pneumonia and hospital acquired pneumonia.
About Antimicrobial Peptides and AMPT's Portfolio
Antimicrobial peptides (AMPs) are found in virtually every species, from microbes to humans. They comprise the first line of defense against infection through the innate immune system. The AMPT portfolio of unique antimicrobial peptides overcomes many of the issues associated with AMPs as anti-bacterial therapeutics, most notably potency, spectrum, stability and toxicity. The unique mechanism of action of these compounds and the low rate of resistance development positions these molecules as the next generation of novel anti-bacterials. In addition to their potential as stand-alone therapeutics, the AMPT portfolio, in combination with EnBiotix's engineered bacteriophage platform, further enhances the scope and capabilities of both platforms.
About EnBiotix
EnBiotix is an engineered antibiotics company deploying novel systems and synthetic biology technologies developed by Prof. James J. Collins, the Termeer Professor of Medical Engineering & Science Professor, Department of Biological Engineering, Massachusetts Institute of Technology. These technologies enable the development of both novel antibiotics and potentiators of existing antibiotics which have the potential to transform their spectrum of activity and resistance profile. With drug-resistant and drug-tolerant infections rapidly becoming a global health crisis, EnBiotix's robust product pipeline addresses a wide range of acute and chronic infections to significantly impact the lives of patients. For more information, please visit www.enbiotix.com.
Contacts
EnBiotix, Inc.
Jeffrey D. Wager, M.D., +1-508-400-1856
Chairman & CEO
